Month: June 2022

WISeKey Announces the Divestiture of arago Zug, Switzerland, June 27, 2022 – Ad-Hoc announcement pursuant to Art. 53 of SIX Listing Rules – WISeKey International Holding Ltd. (“WISeKey” or the “Company”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, AI and IoT company, announced today that it has transferred its 51% controlling interest in arago GmbH (“arago”) to OGARA GmbH (“OGARA”). As previously announced on April 25, 2022, WISeKey signed a Share Purchase and Transfer Agreement to sell its 51% stake in arago to a German consortium of investors led by arago’s founder through his investment company, OGARA. The transfer of the shares gives OGARA full control of arago’s operations into the acquiring consortium, and establish the framework of the partnership between WISeKey and arago to work together on the increasing adoption...

The VENTANA DP 600 is Roche’s new, high-capacity slide scanner that creates high-resolution, digital images of stained tissue samples that help to diagnose cancer and determine a patient’s treatment. Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.1 Many cancers can be cured if detected early and treated effectively.1 The Roche Digital Pathology solution helps empower the digital transformation of pathology and enable better, more personalised healthcare.Basel, 28 June 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE launch of the next-generation VENTANA DP 600 slide scanner (CE-IVD marked). This high-capacity slide scanner produces excellent image quality of stained histology slides from patient tissue samples, while providing ease-of-use...

Ceftobiprole met primary and secondary efficacy endpoints Basilea plans to submit a New Drug Application (NDA) in the U.S. around year end 2022Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, June 28, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today positive topline results for the phase 3 ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcus aureus (SAB).1 Basilea is planning to submit a New Drug Application (NDA) for ceftobiprole to the U.S. Food and Drug Administration (FDA) around year end 2022. In accordance with the agreed Special Protocol Assessment (SPA), Basilea will seek approval for SAB and acute bacterial skin and skin structure infection (ABSSSI) indications based on...

MONTREAL, June 28, 2022 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier” or the “Corporation”) today announced certain matters with respect to its cash tender offer previously announced on June 13, 2022 (the “Tender Offer”) to purchase for cash up to US$350,000,000 aggregate purchase price (exclusive of Accrued Interest) (as such aggregate purchase price may be increased or decreased by the Corporation, the “Aggregate Maximum Purchase Amount”) of three series of its outstanding senior notes (collectively, the “Notes”) due 2027, 2024 and 2025 as identified in the Offer to Purchase (as defined below), subject to the Acceptance Priority Levels and the 2027 Tender Cap (as such 2027 Tender Cap may be increased or decreased by the Corporation), as applicable, and possible proration, as set forth in the Offer to Purchase containing the...

NEW YORK, New York, June 27, 2022 (GLOBE NEWSWIRE) — Ivanhoe Electric Inc. (“Ivanhoe Electric”), a U.S.-based minerals exploration and development company, announced today the pricing of its initial public offering of 14,388,000 shares of its common stock at a price of US$11.75 per share. The gross proceeds from the offering are expected to be approximately US$169.1 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Ivanhoe Electric. In addition, Ivanhoe Electric has granted the underwriters a 30-day option to purchase up to an additional 2,158,200 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the NYSE American and the Toronto Stock Exchange on June 28, 2022 under the ticker...

Pursued Claims Pursued Claims: Paid and Bill AmountCORAL GABLES, Fla., June 27, 2022 (GLOBE NEWSWIRE) — MSP Recovery, Inc. (“MSP Recovery” or “MSPR”), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery and technology leader, today provided a business update.MSP has commenced sending individual claim demands totaling more than $5.6 billion in billed amounts for payments due from some of the largest pharmaceutical companies in the world. The total amounts billed against identified pharmaceutical companies related to more than twenty-five different types of recoveries.MSPR Identifies Additional Owned Claims Against Big Pharma MSPR today announced that it has identified more than $5.6 billion in billed amounts and more than $2.8 billion in paid amounts for unique potentially recoverable cases on behalf...

Approves spin-out of clinics business to Field Trip Health & Wellness Ltd., pending final court approval and additional customary closing conditions TORONTO, June 27, 2022 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (“Field Trip” or “Corporation”), a global leader in the development and delivery of psychedelic therapies, today announced that on June 27, 2022, its shareholders approved both the Arrangement Resolution, the Concurrent Financing Resolution and the SpinCo Incentive Plan Resolution (each as defined in the Circular (each as defined below)) at its special meeting of shareholders (the “Meeting”), thereby approving the previously announced spin-out of its clinics business to Field Trip Health & Wellness Ltd. (“Field Trip H&W”) by way of a...

CALGARY, Alberta and TORONTO, June 27, 2022 (GLOBE NEWSWIRE) — Magnetic North Acquisition Corp. (TSXV: MNC; MNC.PR.A) (“Magnetic North” or the “Company”) is pleased to announce that fiscal year results for the period ended December 31, 2021 and first ‎quarter fiscal results for the period ended March 31, 2022 have been filed on SEDAR.‎ As a result of a review conducted by the Company’s new auditor and management’s consideration of the ‎application of IFRS 10 (Consolidation Financial Statements) for the Company’s investment companies‎, the Company restated its December 31, 2020 comparative financials in its December 31, 2021 audited financial statements. The Company reviewed for qualification as an investment entity and determined that it met this criteria and considers itself an investment entity for both years ended December 30,...

Vancouver, BC, June 27, 2022 (GLOBE NEWSWIRE) — Recharge Resources Ltd. (“Recharge” or the “Company”) (RR: CSE) (RECHF: OTC) (SL5: Frankfurt) is pleased to report that it has applied for and is awaiting the approval of diamond drilling permits for its 100% owned Brussels creek Copper-Gold-Palladium property, located in the Kamloops Mining District, British Columbia. The fully funded Phase 1 Drill Program was designed based on the results of the previously announced Induced Polarization (IP) survey to establish the potential for copper-gold mineralization similar to mineralization present at the adjacent New Afton mine owned by New Gold Inc. (NGD – TSX). The interpretation led to the selection of five high-priority drill targets, with each hole approximately 300 m in depth, for a total proposed program of 1500 metres. The targets...

VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) — P2 Gold Inc. (“P2” or the “Company”) (TSX-V:PGLD) reports that, subject to regulatory approval, it has entered into an agreement (the “Amending Agreement”) amending the terms of the option agreement (the “Option Agreement”) dated June 10, 2020 pursuant to which the Company can acquire up to a 100% interest in the Silver Reef Property located in northwest British Columbia. Under the terms of the Option Agreement, the Company initially has the right to acquire up to a 70% interest in the Silver Reef Property by paying to the vendor over a three-year option period $750,000 and issuing 1.2 million common shares in its capital (“Common Shares”) as follows: $50,000 (paid) and 200,000 Common Shares (issued) on the signing of the Option Agreement; $200,000 (paid) and 200,000...